Recap: Bio-Rad Laboratories Q2 Earnings

Shares of Bio-Rad Laboratories BIO moved higher by 0.2% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 119.88% over the past year to $3.54, which beat the estimate of $2.66.

Revenue of $715,931,000 higher by 33.35% year over year, which beat the estimate of $631,780,000.

Outlook

Bio-Rad Laboratories hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jul 29, 2021

Time: 06:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/ja7vjcij

Technicals

52-week high: $710.79

Company's 52-week low was at $472.84

Price action over last quarter: Up 12.22%

Company Profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!